|
|
|
| Strategies for immunotherapeutic targeting of regulatory T cells in tumor microenvironment |
| LIU Jialing1* WANG Shimin1* ZHUO Zhaozhen2 YUAN Jun3 |
1.Zunyi Medical University, Guizhou Province, Zunyi 563000, China;
2.Department of Clinical Laboratory, People's Hospital of Guizhou Province, Guizhou Province, Guiyang 550002, China; 2.Department of Clinical Laboratory, People′s Hospital of Guizhou Province, Guizhou Province, Guiyang 550002, China;
3.Department of Clinical Laboratory, the Second People′s Hospital of Guiyang, Guizhou Province, Guiyang 550023, China |
|
|
|
Abstract Regulatory T cell (Treg) is a group of lymphocytes with negetive regulation of inhibiting tumor-associated antigen T cell-mediated immune responses, targeted agents may influence tumor immunotherapy and vaccine activation. Systemic removal of CD25+CD4+ T cells perhaps elicit tumor growth in rodents, but also increasing the severity of the autoimmune diseases as peripheral self-tolerance is maintained by Treg cells. According to sources of Regulatory T cells, it can be classfied as two population of nTreg and iTreg cells. Regulatory T cells are phenotypically diversity and functionally heterogeneous in different types of tumor and tissues, whereas conferring the same marker of CD4, CD25 and foxp3. Because of its tumor heterogeneity and organ heterogeneity, therefore, the strategy of targeting Treg cells in tumor immunotherapy is different. On the other hand, removal Treg cell strategies is different in tumor immunotherapy, it can remove regulatory T cells (Treg) or dampen the function of Treg cells through limit its immunosuppression protein, such as GITR, T-bet, Neoropilin-1, CTLA-4, IDO or PD-1. The autoimmunities can be prevented by inoculating OVA vaccine when removing Tregs .Ipilimumab, which has recently been FDA-approved for therapy patients with advanced melanoma mechnism is targeting CTLA- 4 in Treg cells. In this paper, we review the phenotype, heterogeneity and tumor therapy strategies of Treg treatment in order to avoid immune disorders in the future.
|
|
|
|
|
|
[1] Bennett CL，Christie J，Ramsdell F，et al. The immune dysregulation，polyendocrinopathy，enteropathy，X-linked syndrome （IPEX） is caused by mutations of FOXP3 [J]. Nature Genetics，2001，27（1）：20.
[2] Hori S，Nomura T，Sakaguchi S. Control of Regulatory T Cell Development by the Transcription Factor Foxp3 [J]. Science，2003，299（5609）：1057.
[3] Vignali DA，Collison LW，Workman CJ. How regulatory T cells work [J]. Nature Reviews Immunology，2008，8（7）：523.
[4] Rothstein DM，Camirand G. New insights into the mechanisms of Treg function [J]. Current Opinion in Organ Transplantation，2015，20（4）：376.
[5] Zhao H，Liao X，Kang Y. Tregs: Where We Are and What Comes Next? [J]. Front Immunol，2017，8.
[6] Fontenot JD，Gavin MA，Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells [J]. Nature Immunology，2003，4（4）：330.
[7] Zhou X，Jeker LT，Fife BT，et al. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity [J]. Journal of Experimental Medicine，2008，205（9）：1983-1991.
[8] Deng G，Nagai Y，Xiao Y，et al. Pim-2 Kinase Influences Regulatory T Cell Function and Stability by Mediating Foxp3 Protein N-terminal Phosphorylation [J]. Journal of Biological Chemistry，2015，290（33）：20211-20220.
[9] Fontenot JD，Rasmussen JP，Williams LM，et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3 [J]. Immunity，2005，22（3）：329-341.
[10] Levings MK，Sangregorio R，Roncarolo MG. Human cd25（+）cd4（+） t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function [J]. Journal of Experimental Medicine，2001，193（11）：1295-1302.
[11] Zhao Y，Guo H，Qiao G，et al. E3 Ubiquitin Ligase Cbl-b Regulates Thymic-Derived CD4+CD25+ Regulatory T Cell Development by Targeting Foxp3 for Ubiquitination [J]. Journal of Immunology，2015，194（4）：1639-1645.
[12] Seddiki N，Santnernanan B，Martinson J，et al. Expression of interleukin （IL）-2 and IL-7 receptors discriminates between human regulatory and activated T cells [J]. Journal of Experimental Medicine，2006，203（7）：1693-1700.
[13] Liu W，Putnam AL，Zhou XY，et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+T reg cells [J]. Journal of Experimental Med?鄄icine，2006，203（7）：1701-1711.
[14] Collison LW，Workman CJ，Kuo TT，et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function [J]. Nature，2007，450（7169）：566.
[15] Nishikawa H. Regulatory T cells in cancer immunotherapy [J]. Rinsho Ketsueki，2014，55（10）：2183-2189.
[16] Sato E，Olson SH，Nishikawa H，et al. Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes and a High CD8+/regulatory T Cell Ratio Are Associated with Favorable Prognosis in Ovarian Cancer[J]. Proceedings of the National Academy of Sciences of the United States of America，2005，102（51）：18538.
[17] Gavin MA，Rasmussen JP，Fontenot JD，et al. Foxp3-dependent programme of regulatory T-cell differentiation [J]. Nature，2007，445（7129）：771-775.
[18] Miyara M，Yoshioka Y，Kitoh A，et al. Functional delineation and differentiation dynamics of human CD4+T cells expressing the FoxP3 transcription factor [J]. Immunity，2009，30（6）：899.
[19] Liu J，Zhang N，Li Q，et al. Tumor-Associated Macrophages Recruit CCR6+Regulatory T Cells and Promote the Development of Colorectal Cancer via Enhancing CCL20 Production in Mice [J]. PLoS One，2011，6（4）：e19495.
[20] Sugiyama D，Nishikawa H，Maeda Y，et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells，evoking antitumor immune responses in humans [J]. Proceedings of the National Academy of Sciences of the United States of America，2013，110（44）：17945-17950.
[21] Spranger S，Spaapen RM，Zha Y，et al. Up-Regulation of PD-L1，IDO，and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+T Cells [J]. Science Translational Medicine，2013，5（200）：200ra116.
[22] Song M，Chen D，Lu B，et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer [J]. PLoS One，2013，8（6）：e65821.
[23] Steinbrink K，Jonuleit H，Müller G，et al. IL-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+，T cells resulting in a failure to lyse tumor cells [J]. Journal of Dermatological Science，1999， 16（5）：1634-1642.
[24] Hao C，Tian J，Liu H，et al. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials [J]. Medicine，2017，96（26）：e7325.
[25] Simpson TR，Li F，Montalvoortiz W，et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma [J]. Journal of Experimental Medicine，2013， 210（9）：1695-1710.
[26] Shimizu J，Yamazaki S，Takahashi T，et al. Stimulation of CD25（+）CD4（+） regulatory T cells through GITR breaks immunological self-tolerance [J]. Nature Immunology，2002，3（2）：135.
[27] Valzasina B，Guiducci C，Dislich H，et al. Triggering of OX40 （CD134） on CD4（+）CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR [J]. Blood，2005，105（7）：2845.
[28] Dannull J，Su Z，Rizzieri D，et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells [J]. Journal of Clinical Investigation，2005，115（12）：3623-3633.
[29] Mahnke K，Sch?觟nfeld K，Fondel S，et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro [J]. International Journal of Cancer Journal International Du Cancer，2007，120（12）：2723-2733.
[30] Katharina L，Christoph L，Cathy D，et al. Selective depletion of Foxp3+regulatory T cells induces a scurfy-like disease [J]. Journal of Experimental Medicine，2007，204（1）：57-63.
[31] Klages K，Mayer CK，Loddenkemper C，et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma [J]. Cancer Research，2010，70（20）：7788-7799.
[32] Rech AJ，Mick R，Martin S，et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients [J]. Science Translational Medicine，2012，4（134）：134ra62.
[33] Rech AJ，Mick R，Recio A，et al. Phase I study of anti-CD25 mab daclizumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients （pts） with metastatic breast cancer （MBC）[J]. Journal of Clinical Oncology，2010，28（15_suppl）,2508.
[34] de Vries IJ，Castelli C，Huygens C，et al. Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research，2011，17（4）：841.
[35] Sutmuller RPM，Van DLM，Andrea VE，et al. Synergism of Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade and Depletion of Cd25+Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses [J]. Journal of Experimental Medicine，2001，194（6）：823.
[36] Dudda JC，Perdue N，Bachtanian E，et al. Foxp3+ regulatory T cells maintain immune homeostasis in the skin [J]. Journal of Experimental Medicine，2008，205（7）：1559-1565.
[37] Schneider MA，Meingassner JG，Martin L，et al. CCR7 is required for the in vivo function of CD4+CD25+regulatory T cells [J]. Journal of Experimental Medicine，2007，204（4）：735.
[38] Yamazaki T，Yang XO，Chung Y，et al. CCR6 Regulates the Migration of Inflammatory and Regulatory T Cells [J]. Journal of Immunology，2008，181（12）：8391-8401.
[39] Redjimi N，Raffin C，Raimbaud I，et al. CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity [J]. Cancer Research，2012，72（17）：4351-4360.
[40] Ohtani H，Yoshie O. Morphometric analysis of the balance between CXCR3+ T cells and FOXP3+ regulatory T cells in lymphocyte-rich and conventional gastric cancers [J]. Virchows Archiv An International Journal of Pathology，2010，456（6）：615.
[41] Blatner NR，Mulcahy MF，Dennis KL，et al. Expression of RORγt Marks a Pathogenic Regulatory T Cell Subset in Human Colon Cancer [J]. Science Translational Medicine，2012，4（164）：164ra159. |
|
|
|
